Dihydroartemisinin Protects against Dextran Sulfate Sodium-Induced Colitis in Mice through Inhibiting the PI3K/AKT and NF-κB Signaling Pathways

Ning Li,1 Wenjing Sun,1 Xin Zhou,2 Hao Gong,1 Yuqing Chen,1 Dongfeng Chen,1 and Fei Xiang2

1Department of Gastroenterology, Daping Hospital, Army Medical University, Chongqing 400030, China
2Institute of Burn Research, State Key Laboratory of Trauma, Burns and Combined Injury, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, China

Correspondence should be addressed to Dongfeng Chen; chendf1981@126.com and Fei Xiang; 22267919@qq.com

Received 29 April 2019; Revised 17 August 2019; Accepted 17 September 2019; Published 6 November 2019

Copyright © 2019 Ning Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ulcerative colitis is a common inflammatory bowel disease, and the activation of the PI3K/AKT and NF-κB signaling pathways plays a pivotal role in its pathogenesis. Dihydroartemisinin (DHA) is a widely used antimalarial drug and has shown anticancer effect partially through inhibiting the activation of PI3K/AKT and NF-κB. This study aimed to investigate the effect of dihydroartemisinin on ulcerative colitis and its mechanism. Adult male C57 mice were subjected to 3.0% dextran sulfate sodium (DSS) for seven days; simultaneously, dihydroartemisinin or control saline was administered by oral gavage once a day. In vitro, the intestinal epithelial cell-6 was treated with LPS for 24 hours with or without dihydroartemisinin combined with PI3K/Akt activator 740 Y-P or NF-κB activator phorbol myristate acetate. Western blotting was used to test the activation of PI3K/AKT and NF-κB. Dihydroartemisinin significantly ameliorated body weight loss, shortened colon length, and increased DAI in DSS-induced colitis. Meanwhile, histological damage was improved and was accompanied by decreased expression and secretion of proinflammatory cytokines. Moreover, DSS-induced elevation of phosphorylation of PI3K, AKT, IKKα, IκBα, and NF-κB (p65) was remarkably blunted by dihydroartemisinin both in vivo and in vitro, indicating an inhibitive property on the PI3K/AKT and NF-κB signaling pathways. Furthermore, administration of 740 Y-P or PMA significantly blocked protective activity of dihydroartemisinin against colitis in vitro. In conclusion, dihydroartemisinin can attenuate DSS-induced colitis, and its anticolitis effect might be mediated via the PI3K/AKT and NF-κB signaling pathways. DHA might serve as a promising drug for patients with ulcerative colitis.

1. Introduction

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) caused by a combination of environmental and genetic factors and is characterized by inflammation, homeostasis disruption, and epithelial barrier damage in the intestinal tract [1, 2]. UC affects millions of people worldwide, and its morbidity increases yearly. The clinical manifestations of UC include development of bloody diarrhea with or without mucus, weight loss, abdominal pain, rectal urgency, tenesmus, and even systemic symptoms in severe cases [3]. Currently, the main therapy for UC is anti-inflammatory treatment using nonsteroid drugs such as mesalamine and corticosteroids. However, the nonsteroid drugs lack a universal response and have potential adverse side effects, such as infection and neoplasia. Therefore, it is urgent to develop new drugs for safer and more effective treatment of UC.

So far, although the pathophysiology of UC is not fully understood, promising advances have been achieved in the knowledge of inflammatory and immune mechanisms [4]. Many cellular signaling pathways, such as MAPK/AP-1, Nrf2, PPAR-α, PI3K/AKT, and NF-κB, are generally believed to be involved in inflammatory and immune disorders in UC. For example, rSj16 can inactivate the PPAR-α
signaling pathway to inhibit immune inflammatory responses and protect against DSS-induced colitis [5]. LL202 protects against experimental colitis in mice by inhibiting MAPK/AP-1 signaling to decrease the expression of proinflammatory factors [6]. Notably, PI3K/AKT and NF-κB signaling pathways are appealing for their crucial role in pathogenesis and progress of UC and are regarded as an important target for UC treatment. The PI3K/AKT signaling pathway is involved in release of proinflammatory cytokines, such as TNF-α in the intestinal mucosa in UC patients, and targeting this pathway can provide the basis for development of new drugs for UC [7, 8]. Activation of the NF-κB signaling pathway plays a central role in regulating an immune inflammatory response in UC, and there is evidence that inactivation of NF-κB can attenuate experimental colitis [4, 9].

Dihydroartemisinin (DHA) is an artemisinin derivative and is widely used as a first-line antimalarial drug. Additionally, growing evidence has shown that dihydroartemisinin exerts beneficial effects in many diseases, especially in cancer [10–12]. For example, dihydroartemisinin can attenuate hepatocyte lipaoptosis and liver fibrosis [13, 14]. Dihydroartemisinin also inhibits the growth of squamous cell carcinoma cells and colorectal carcinoma cells [10]. These effects were partially mediated by its inhibitory property on the PI3K/AKT and NF-κB signaling pathways [15–17]. However, whether dihydroartemisinin exerts a protective effect against UC is unknown. In the present study, we tested the effect of dihydroartemisinin on DSS-induced colitis and found that it significantly attenuated DSS-induced colitis and inhibited the expression of proinflammatory factors. We also revealed that dihydroartemisinin played an anticolitis role through inhibiting the PI3K/AKT and NF-κB signaling pathways.

2. Materials and Methods

2.1. Induction and Evaluation of Colitis in Mice. Four-month-old C57BL/6J male mice were obtained from the Laboratory Animal Center of Daping Hospital. All experimental procedures were in accordance with institutional regulations and approved by the Experimental Animals Committee of Daping Hospital. Animals were randomly allocated into three groups: control group (N = 8), DSS group (N = 8), and DSS+DHA group (N = 8 for each dose). Colitis was induced by replacing drinking water with 3.5% DSS (MP Biomedicals, USA) for seven days. Meanwhile, DHA was administered by oral gavage once a day for 7 days. According to a previous study, dose of dihydroartemisinin varying from 10 mg/kg to 50 mg/kg has been widely used in many animal models such as cancer and it showed great efficacy and safety [18–21]. Therefore, doses of 10, 25, and 50 mg/kg were selected in the present study to test dihydroartemisinin’s protective effect against DSS-induced colitis. Body weight loss, stool consistency, and fecal blood loss were observed and recorded daily. The clinical course of colitis was evaluated by a daily disease activity index consisting of the three parameters, stool consistency, weight loss, and the presence of blood in feces and the anus, as previously described [22]. At day 7, animals were euthanized with an overdose of isoflurane and the colon and blood samples were collected. Then, colon length was measured, and the colon was stored for subsequent experiments.

2.2. Histopathology Analysis. Histopathology of the colon was examined using hematoxylin-eosin (H&E) staining as previously described [23]. Briefly, approximately 0.5 cm of the descending colon was obtained and cleaned with normal saline. Then, samples were fixed with 4% paraformaldehyde, dehydrated, and paraffin embedded prior to being sectioned continuously at a thickness of 4 μm. The colon sections were dehydrated, stained with hematoxylin and eosin, and mounted in permount. Then, the sections were observed with a microscope to observe morphological changes. Histopathological scores of the colonic lesions were determined as previously described by evaluation of inflammation, crypt damage, submucosal edema, and reactive epithelial hyperplasia [5].

2.3. ELISA Analysis. Colon homogenate supernatants and serum were collected, and the concentrations of TNF-α, IL-6, and IL-1β were measured by using ELISA kits following the manufacturer’s instructions (NeoBioscience, China).

2.4. Cell Culture. Intestinal epithelial cell-6 (IEC-6) was cultured in DMEM medium and was treated with LPS (1 μg/ml) for 24 hours to establish in vitro colitis model. Dihydroartemisinin (100 μM) with/without PI3K/Akt activator 740 Y-P (25 μg/mL) or NF-κB activator phorbol myristate acetate (PMA, 1 μM) was administrated for 24 hours. Then, cells were collected and stored at −80°C for western blotting and quantitative real-time PCR.

2.5. Quantitative Real-Time PCR. Total RNA was isolated from the colon tissue or IEC-6 cells using RNAiso plus (Takara, Japan) following the manufacturer’s instructions, and reverse transcription polymerase chain reaction (RT-PCR) was performed using the TOYOBO RT-PCR kit. The Applied Bio systems 7500 Fast Real-Time PCR System was used to perform SYBR Green quantitative PCR of TNF-α, IL-6, and IL-1β. Quantification of mRNA expression was normalized against GAPDH using the double delta Cq method. The primers used are listed in Table 1.

2.6. Western Blotting Analysis. The activation of the PI3K/AKT and NF-κB signaling pathways in colon tissue was measured by western blotting. The total protein of colon tissues was extracted using RIPA lysis buffer containing a protease inhibitor cocktail (Beyotime Biotechnology, China), and protein concentrations were measured using a Bradford protein assay kit (Bio-Rad, USA). The proteins were separated by SDS-PAGE and then electrotransferred to PVDF membranes. The membranes were then blocked with 5% nonfat skim milk and incubated with primary antibodies overnight at 4°C. Then, membranes were washed with TBST
and incubated with secondary antibody (goat anti-rabbit IR Dye 800, Invitrogen) for 1 hour at room temperature, followed by visualization with an Odyssey Infrared Imaging System (Li-Cor Biosciences, Lincoln, NE) and analysis using Quantity One image analysis software. GAPDH was used as an internal control to normalize the expression of protein. The antibodies used were as follows: PI3K (1:1000; Cell Signaling Technology), phosphor-PIK3 (1:1000; Cell Signaling Technology), AKT (1:1000; Abcam), p-AKT (1:800; Abcam), NF-κB (1:800; Abcam), IKKα (1:800; Abcam), and GAPDH (1:1000; Cell Signaling Technology).

2.7. Statistical Analysis. All results are expressed as means ± SD. Statistical analysis was performed using SPSS 18.0 software. Comparison of means between two groups was performed using the two-tailed Student’s t-test. Comparison of means among more than two groups was performed by one-way ANOVA followed by Holm–Sidak’s post hoc multiple comparison test. 

3. Results

3.1. Dihydroartemisinin Ameliorated DSS-Induced Colitis in Mice. To explore whether dihydroartemisinin exerts therapeutic effects on colitis, we established a mouse model of DSS-induced colitis and dihydroartemisinin was administered daily at various doses by oral gavage for 7 days. The results showed that DSS induced drastic body weight loss, and dihydroartemisinin administration significantly blunted the body weight loss in a dose-dependent manner (Figure 1(a)). In addition, DSS induced a significant shortening of the colon length (Figures 1(b) and 1(c)), which is a marker of sufficient induction of colitis and is inversely associated with the severity of colitis. Consistent with attenuated body weight loss, the shortening of the colon length was significantly improved by dihydroartemisinin in a dose-dependent manner (Figures 1(b) and 1(c)). To further investigate the effect of dihydroartemisinin on DSS-induced colitis, evaluation of DAI (disease activity index) was performed. As shown in Figure 1(d), DSS induced a DAI increase during disease progression, and this elevation was relieved by dihydroartemisinin from day 4 onward. Macropscopic analysis of the colon revealed that DSS induced a significant increase in the macroscopic colon damage scores which was characterized by hyperemia, ulceration, and bowel wall thickening (Figure 1(e)). Notably, macroscopic colon damage scores in the dihydroartemisinin group were significantly lower than those in the DSS group, indicating improvement of colon damage (Figure 1(e)).

3.2. Dihydroartemisinin Reduced Microscopic Colon Damage in DSS-Induced Colitis. To further investigate the histological changes in the colons, H&E staining was carried out. Our results showed that compared with the control group, the colon specimens in the DSS group displayed severe mucosal damage, distortion of crypts, infiltration of mononuclear cells, and loss of goblet cells, confirming that the model of DSS-induced colitis in mice was successfully established (Figure 2(a)). Consistent with the observed anticolitis effect in Figure 1, dihydroartemisinin largely restored DSS-induced histopathological abnormalities, which was further confirmed by microscopic scores (Figures 2(a) and 2(b)). Collectively, these results suggested that dihydroartemisinin can reduce microscopic colon damage, consistent with its therapeutic effect in colitis.

3.3. Dihydroartemisinin Inhibited Production of Proinflammatory Cytokines in DSS-Induced Colitis. As proinflammatory factors play important roles in the pathogenesis and progress of UC [24], we investigated whether dihydroartemisinin inhibits production of proinflammatory cytokines in the colon and serum. As shown in Figures 3(a)–3(c), DSS induced a significant increase in mRNA expression of TNF-α, IL-6, and IL-1β, and these changes were blocked by dihydroartemisinin in a dose-dependent manner, indicating that the transcription of these cytokines was inhibited by dihydroartemisinin. In addition, ELISA analysis of the colonic homogenized protein revealed that the protein levels of TNF-α, IL-6, and IL-1β were remarkably increased in the DSS group compared to those in the control group (Figures 3(d)–3(f)). Similarly, administration of dihydroartemisinin inhibited the production of these cytokines in a dose-dependent manner (Figures 3(d)–3(f)). Furthermore, similar alterations of serum TNF-α, IL-6, and IL-1β were observed (Figures 3(g)–3(i)). These data suggested that dihydroartemisinin exerts an anti-inflammatory effect in colitis, and this effect may account for its therapeutic role in DSS-induced colitis.

3.4. Dihydroartemisinin Blocked the Activation of PI3K/AKT and NF-κB Signaling Pathways in Colitis Both In Vivo and In Vitro. Since the PI3K/AKT and NF-κB signaling pathways play essential roles in colitis [25–28], we next determined the effect of dihydroartemisinin on the PI3K/AKT and NF-κB

| Table 1: Primers for real-time PCR. |
|-----------------------------------|
| Primer name | Species | Sequence |
|----------------|---------|----------|
| TNF-α forward | Mouse | CCCTCACCTGCAACACAC |
| TNF-α reverse | Mouse | ATAGCACAACCCCTGACAG |
| IL-6 forward | Mouse | ACAAAAGCAGTCCTCCAGAG |
| IL-6 reverse | Mouse | TGTGACTTCAGTTCTCCTGAGG |
| IL-1β forward | Mouse | TGGCACTTTTTGACAGTATG |
| IL-1β reverse | Mouse | AGGTTCACCGGAAAAAGACAC |
| GAPDH forward | Mouse | CCCCCAAAGAGGAGTCCG |
| GAPDH reverse | Mouse | TACGCCCCAATCCCGTTCACA |
| TNF-α forward | Rat | ATGGGCTCCCTCCTCATCAATG |
| TNF-α reverse | Rat | TGCTTGGTGCTGTCTACGA |
| IL-6 forward | Rat | AGGGAATGTGCAGCTGTCAGA |
| IL-6 reverse | Rat | GGAACCTCCAGAACAGAGC |
| IL-1β forward | Rat | GACTTCACCATGGAACCCGT |
| IL-1β reverse | Rat | CAGGGAGGGAAACACAGT |
| GAPDH forward | Rat | AGTGCAGGCTCGTCCTACA |
| GAPDH reverse | Rat | GATGGTGATGGGTTCCTCCG |

**Table 1:** Primers for real-time PCR.

- **TNF-α forward**: Mouse, Sequence: CCCTCACCTGCAACACAC
- **TNF-α reverse**: Mouse, Sequence: ATAGCACAACCCCTGACAG
- **IL-6 forward**: Mouse, Sequence: ACAAAAGCAGTCCTCCAGAG
- **IL-6 reverse**: Mouse, Sequence: TGTGACTTCAGTTCTCCTGAGG
- **IL-1β forward**: Mouse, Sequence: TGGCACTTTTTGACAGTATG
- **IL-1β reverse**: Mouse, Sequence: AGGTTCACCGGAAAAAGACAC
- **GAPDH forward**: Mouse, Sequence: CCCCCAAAGAGGAGTCCG
- **GAPDH reverse**: Mouse, Sequence: TACGCCCCAATCCCGTTCACA
- **TNF-α forward**: Rat, Sequence: ATGGGCTCCCTCCTCATCAATG
- **TNF-α reverse**: Rat, Sequence: TGCTTGGTGCTGTCTACGA
- **IL-6 forward**: Rat, Sequence: AGGGAATGTGCAGCTGTCAGA
- **IL-6 reverse**: Rat, Sequence: GGAACCTCCAGAACAGAGC
- **IL-1β forward**: Rat, Sequence: GACTTCACCATGGAACCCGT
- **IL-1β reverse**: Rat, Sequence: CAGGGAGGGAAACACAGT
- **GAPDH forward**: Rat, Sequence: AGTGCAGGCTCGTCCTACA
- **GAPDH reverse**: Rat, Sequence: GATGGTGATGGGTTCCTCCG

**Table 1:** Primers for real-time PCR.
Figure 1: Continued.
Figure 1: Dihydroartemisinin protects against DSS-induced colitis in mice. (a) Changes in body weight were recorded daily. (b) Representative images of colons on day 7. (c) Quantification of colon lengths on day 7. N = 8 in each group. (d) The disease activity index (DAI) of mice on day 7. N = 8 in each group. (e): Histological scores were assessed to evaluate macroscopic colon damage. N = 8 in each group. *p < 0.05 vs. control group. #p < 0.05 vs. DSS group.

Figure 2: Dihydroartemisinin reduces microscopic colon damage in DSS-induced colitis. (a) Representative images of colonic tissue sections with hematoxylin & eosin (H&E) staining. (b) Histopathological scores were determined. N = 8 in each group. *p < 0.05 vs. control group. #p < 0.05 vs. DSS group.
Figure 3: Continued.
Figure 3: Dihydroartemisinin inhibits production of proinflammatory cytokines in the colon. (a–c) mRNA levels of TNF-α, IL-6, and IL-1β in colonic homogenates determined by qRT-PCR. N = 4 in each group. (d–f) Protein levels of TNF-α, IL-6, and IL-1β in colonic homogenates determined by ELISA. N = 5 in each group. (g–i): Serum concentrations of TNF-α, IL-6, and IL-1β determined by ELISA. N = 6 in each group. *p < 0.05 vs. control group. #p < 0.05 vs. DSS group.

Figure 4: Continued.
Figure 4: Dihydroartemisinin blocks activation of the PI3K/AKT signaling pathway in colitis both in vivo and in vitro. The mice were treated with DSS for 7 days and IEC-6 cells were treated with LPS for 24 hours, and then, the colon tissue and IEC-6 cell lysates were analyzed by western blotting. (a): Representative image of p-PI3K, PI3K, p-AKT, and AKT in colon tissues. (b): Quantification analysis of p-PI3K/PI3K and p-AKT/AKT in colon tissues. N=4 in each group. *p<0.05 vs. control group. #p<0.05 vs. DSS group. (c) Representative image of p-PI3K, PI3K, p-AKT, and AKT in IEC-6 cells. (d) Quantification analysis of p-PI3K/PI3K and p-AKT/AKT in IEC-6 cells. N=4 in each group. (e) Relative mRNA expression of TNF-α, IL-6, and IL-1β in IEC-6 cells. N=4 in each group. *p<0.05 vs. control group; #p<0.05 vs. LPS group; and p<0.05 vs. LPS + DHA group.

Figure 5: Continued.
Western blotting results showed that DSS treatment increased the level of p-PI3K and p-AKT and the relative level of p-PI3K/PI3K and p-AKT/AKT in colon tissue, indicating the activation of PI3K/AKT cascades (Figures 4(a) and 4(b)). Notably, administration of dihydroartemisinin largely blocked the activation of the PI3K/AKT signaling pathway, which was indicated by lower p-PI3K/PI3K and p-AKT/AKT (Figures 4(a) and 4(b)). Similarly, LPS treatment increased the level of p-PI3K and p-AKT and the relative level of p-PI3K/PI3K and p-AKT/AKT in cultured IEC-6 cells, and these alterations were significantly ameliorated by dihydroartemisinin (Figures 4(c) and 4(d)). Furthermore, dihydroartemisinin blocked LPS-induced upregulation of TNF-α, IL-6, and IL-1β in IEC-6 cells, and this effect was partially blocked by administration of PI3K/AKT activator 740Y-P (Figure 4(e)), demonstrating that dihydroartemisinin protects against colitis partially through inhibiting activation of PI3K/AKT signaling pathway.

DSS also induced activation of the NF-κB signaling pathway in colon tissue, indicated by increased phosphorylation of IKKα/IκBa and NF-κB (p65), which was inhibited
by dihydroartemisinin (Figures 5(a) and 5(b)). In vitro results showed that LPS treatment induced elevation in phosphorylation of IKKa/IKBα and NF-κB (p65), and these alterations were blocked by dihydroartemisinin (Figures 5(c) and 5(d)). Protective effect of dihydroartemisinin against colitis was also observed in vitro, and this effect was partially blocked by administration of NF-κB activator PMA (Figure 5(e)). Therefore, these results indicated that the PI3K/AKT and NF-κB signaling pathways were activated in colitis, and dihydroartemisinin may exerts its benefits in DSS-induced colitis by inhibiting the activation of both PI3K/AKT and NF-κB signaling pathways.

4. Discussion

In the present study, we investigated the protective effect of dihydroartemisinin on DSS-induced colitis and explored the underlying mechanism. We found that dihydroartemisinin significantly ameliorated body weight loss, shortened the colon length, and increased DAI in DSS-induced colitis. Meanwhile, histological damage was improved, accompanied by decreased expression and secretion of proinflammatory cytokines. For the mechanism, the anti-colitis effect of dihydroartemisinin might be mediated by its inhibition of the PI3K/AKT and NF-κB signaling pathways.

Uc is characterized by inflammation, homeostasis disruption, and epithelial barrier damage in the intestinal tract, and DSS is a well-established agent to induce experimental colitis that is phenotypically similar to UC in humans [29]. DSS-induced colitis is of reasonable reproducibility and of great value for investigating the efficacy of anti-colitis agents. In our study, oral administration of DSS in mice for several days induced significant body weight loss and shortening of the colon length, which was comparable to previous studies [30, 31]. In addition, evaluation of weight loss, stool consistency, and paranal bleeding revealed that DSS induced a dramatic increase in DAI score. Meanwhile, histological damage was observed in the DSS group. These results were consistent with published data in previous reports, confirming successful establishment of DSS-induced colitis. Therefore, these results make our experiments based on DSS-induced colitis reliable.

Although the mechanism of pathogenesis of UC is not yet fully understood, the abnormality of the inflammatory and immune responses has been highly focused on. Evidence from previous studies has demonstrated that interaction between the intestinal mucosal immune system and proinflammatory cytokines can affect intestinal homeostasis and lead to the disruption of tight junction proteins [32]. Disorders in immune responses have been reported to be associated with imbalance between proinflammatory and anti-inflammatory cytokines, and increased expression of proinflammatory cytokines is an important characteristic of UC [4, 29]. In our study, DSS treatment in mice remarkably induced elevation of mRNA expression of TNF-α, IL-6, and IL-1β, which was consistent with previous studies [9, 27]. In addition, the protein levels of these proinflammatory cytokines were also significantly increased after DSS treatment.

Notably, dihydroartemisinin treatment dramatically suppressed the elevation of both colon and serum proinflammatory cytokines. Therefore, we speculated that the protective effect of dihydroartemisinin might be related to inhibition of inflammatory response.

Although, many intracellular signaling pathways are involved in regulating the inflammatory and immune responses, growing evidence has shown that the PI3K/AKT signal transduction pathway plays a pivotal role in regulation of expression and secretion of inflammatory cytokines. In addition, the PI3K/AKT signaling pathway is abnormally activated in UC, leading to enhanced expression and secretion of proinflammatory cytokines such as TNF-α [7, 22]. In addition to the PI3K/AKT signaling pathway, activation of NF-κB can enhance production of proinflammatory cytokines [9, 31, 33]. In the present study, the results showed that DSS and LPS induced activation of PI3K/AKT and NF-κB in vivo and in vitro, respectively, and the activation was prevented by dihydroartemisinin. Furthermore, protective effect of dihydroartemisinin against colitis was partially blocked by PI3K/Akt activator 740 Y-P or NF-κB activator PMA, demonstrating that the anti-inflammatory effect in colitis might be mediated by PI3K/AKT and NF-κB signaling suppression. Dihydroartemisinin has also been reported to inhibit endothelial cell proliferation through the suppression of the MAPK (mainly ERK subfamily) signaling pathway [34]. However, in another study, dihydroartemisinin was reported to activate ERK and p38 MAPK signaling pathways in PC12 cells [35]. In addition, dihydroartemisinin was also reported to suppress TGF-β signaling in the lung and kidney [36, 37]. Therefore, the effect of dihydroartemisinin on these signaling cascades might depend on the cell and organ type and experimental settings. As MAPK and TGFβ signaling pathways involve in pathogenesis of colitis [6], there exists the possibility that dihydroartemisinin also partially regulates MAPK and TGFβ pathways to exert its protective effect against colitis. In addition, there are crosstalks between these signaling pathways. For example, TGFβ was reported to activate PI3K-AKT signaling [38], which further complicated potential regulatory network in colitis. Therefore, further studies are needed to define relationship between these signaling pathways and dihydroartemisinin in colitis.

5. Conclusion

Our results first revealed that dihydroartemisinin can effectively attenuate DSS-induced colitis. In addition, DSS-induced elevation of expression and secretion of proinflammatory cytokines was blocked by dihydroartemisinin. Additionally, the protective effect of dihydroartemisinin might occur through inhibition of both the PI3K/AKT and NF-κB signaling pathways. Notably, dihydroartemisinin has been indicated to be safe in the treatment of malaria and application in cancers. Therefore, dihydroartemisinin might be a promising molecule that has translational potential in the treatment of colitis.
Abbreviations

UC: Ulcerative colitis  
DHA: Dihydroartemisinin  
DSS: Dextran sulfate sodium.

Data Availability

All the data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

NLi, DFChen andFXiang conceived the idea. NLi, WJSun, XZhou, HGong, andYQChen performed the experiments and analyzed the data. NLi andFXiang wrote the manuscript. DFChen andFXiang supervised the study. All of the authors read and approved the final manuscript.

References

[1] S. E. Berends, A. S. Strik, M. Löwenberg, G. R. D’Haens, and R. A. A. Mathôt, “Clinical pharmacokinetic and pharmaco-dynamic considerations in the treatment of ulcerative colitis,” Clinical Pharmacokinetics, vol. 58, no. 1, pp. 15–37, 2019.
[2] T. Larussa, M. Oliverio, E. Suraci et al., “Oleuropein decreases cyclooxygenase-2 and interleukin-17 expression and attenuates inflammatory damage in colonic samples from ulcerative colitis patients,” Nutrients, vol. 9, no. 4, 2017.
[3] W. J. Sandborn, B. G. Feagan, D. C. Wolf et al., “Oznamid induction and maintenance treatment for ulcerative colitis,” New England Journal of Medicine, vol. 374, no. 18, pp. 1754–1762, 2016.
[4] X. Xu, Y. Wang, Z. Wei et al., “Madeccassic acid, the contributor to the anti-colitis effect of madecassoside, enhances the shift of Th17 toward Treg cells via the PPARgamma/AMPK/ACC1 pathway,” Cell Death & Disease, vol. 8, no. 3, Article ID e2723, 2017.
[5] L. Wang, H. Xie, L. Xu et al., “rSj16 protects against DSS-induced colitis by inhibiting the PPAR-α signaling pathway,” Theranostics, vol. 7, no. 14, pp. 3446–3460, 2017.
[6] Y. Gao, Y. Huang, Y. Zhao et al., “LL202 protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting MAPK/AMPK signaling,” Oncotarget, vol. 7, no. 39, pp. 63981–63994, 2016.
[7] S. Setia, B. Nehru, and S. N. Sanyal, “Upregulation of MAPK/Erk and PI3K/Akt pathways in ulcerative colitis-associated colon cancer,” Biomedicine & Pharmacotherapy, vol. 68, no. 8, pp. 1023–1029, 2014.
[8] X. L. Huang, J. Xu, X. H. Zhang et al., “PI3K/Akt signaling pathway is involved in the pathogenesis of ulcerative colitis,” Inflammation Research, vol. 60, no. 8, pp. 727–734, 2011.
[9] T. Tian, Y. Zhou, X. Feng et al., “MicroRNA-16 is putatively involved in the NF-kappaB pathway regulation in ulcerative colitis through adenosine A2a receptor (A2aR) mRNA targeting,” Scientific Reports, vol. 6, Article ID 30824, 2016.
[10] H. Y. Hui, N. Wu, M. Wu, Y. Liu, S.-X. Xiao, and M.-F. Zhang, “Dihydroartemisinin suppresses growth of squamous cell carcinoma A431 cells by targeting the Wnt/β-catenin pathway,” Anti-Cancer Drugs, vol. 27, no. 2, pp. 99–105, 2016.
[11] T. Ontikatze, J. Rudner, R. Handrick, C. Belka, and V. Jendrossek, “Dihydroartemisinin is a hypoxia-active anti-cancer drug in colorectal carcinoma cells,” Frontiers in Oncology, vol. 4, p. 116, 2014.
[12] W. DU, C. Pang, Y. Xue, Q. Zhang, and X. Wei, “Dihydroartemisinin inhibits the Raf/ERK/MEK and PI3K/AKT pathways in glioma cells,” Oncology Letters, vol. 10, no. 5, pp. 3266–3270, 2015.
[13] X. Chen, M. Bion, C. Zhang et al., “Dihydroartemisinin inhibits ER stress-mediated mitochondrial pathway to attenuate hepatocyte lipoapoptosis via blocking the activation of the PI3K/Akt pathway,” Biomedicine & Pharmacotherapy, vol. 97, pp. 975–984, 2018.
[14] Q. Chen, L. Chen, D. Kong, J. Shao, L. Wu, and S. Zheng, “Dihydroartemisinin alleviates bile duct ligation-induced liver fibrosis and hepatic stellate cell activation by interfering with the PDGF-β/ERK signaling pathway,” International Immunopharmacology, vol. 34, pp. 250–258, 2016.
[15] F. Dong, X. Zhou, C. Li et al., “Dihydroartemisinin targets VEGFR2 via the NF-κB pathway in endothelial cells to inhibit angiogenesis,” Cancer Biology & Therapy, vol. 15, no. 11, pp. 1479–1488, 2014.
[16] S. J. Wang, B. Sun, Z.-X. Cheng et al., “Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathway,” Cancer Chemotherapy and Pharmacology, vol. 68, no. 6, pp. 1421–1430, 2011.
[17] S. J. Wang, Y. Gao, H. Chen et al., “Dihydroartemisinin inactivates NF-κB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo,” Cancer Letters, vol. 293, no. 1, pp. 99–108, 2010.
[18] Y. Li, Y. Wang, R. Kong et al., “Dihydroartemisinin suppresses pancreatic cancer cells via a microRNA-mRNA regulatory network,” Oncotarget, vol. 7, no. 38, pp. 62460–62473, 2016.
[19] J. D. Paccez, K. Duncan, D. Sekar et al., “Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl,” Oncogenesis, vol. 8, no. 3, p. 14, 2019.
[20] F. Zhang, Q. Ma, Z. Xu et al., “Dihydroartemisinin inhibits TCTP-dependent metastasis in gallbladder cancer,” Journal of Experimental & Clinical Cancer Research, vol. 36, no. 1, p. 68, 2017.
[21] X. Liu, J. Lu, Y. Liao et al., “Dihydroartemisinin attenuates lipopolysaccharide-induced acute kidney injury by inhibiting inflammation and oxidative stress,” Biomedicine & Pharmacotherapy, vol. 117, Article ID 109070, 2019.
[22] X. F. Wu, R. Xu, Z.-J. Ouyang et al., “Beavurericin ameliorates experimental colitis by inhibiting activated T cells via downregulation of the PI3K/Akt signaling pathway,” PLoS One, vol. 8, no. 12, Article ID e83013, 2013.
[23] J. Li, H. Chen, B. Wang et al., “ZnO nanoparticles act as supportive therapy in DSS-induced ulcerative colitis in mice by maintaining gut homeostasis and activating Nrff2 signaling,” Sci Rep, vol. 7, no. 1, Article ID 43126, 2017.
[24] R. Ungaro, S. Mehandru, P. B. Allen, L. Peyrin-Biroulet, and J. F. Colombel, “Ulcerative colitis,” The Lancet, vol. 389, no. 10080, pp. 1756–1770, 2017.
[25] W. Qian, D. Yu, J. Zhang et al., “Wogonin attenuates ischemia/reperfusion injury in mice by suppressing the PI3K/Akt pathway,” Frontiers in Pharmacology, vol. 9, p. 896, 2018.
[26] Y. He, Y. Ge, M. Jiang et al., “MiR-592 promotes gastric cancer proliferation, migration, and invasion through the PI3K/AKT pathway.”
and MAPK/ERK signaling pathways by targeting Spry2,” Cellular Physiology and Biochemistry, vol. 47, no. 4, pp. 1465–1481, 2018.

[27] H. Kim, N. Banerjee, R. C. Barnes et al., “Mango polyphenolics reduce inflammation in intestinal colitis-involvement of the miR-126/PI3K/AKT/mTOR axis in vitro and in vivo,” Molecular Carcinogenesis, vol. 56, no. 1, pp. 197–207, 2017.

[28] P. K. Bagul, N. Deepthi, R. Sultana, and S. K. Banerjee, “Resveratrol ameliorates cardiac oxidative stress in diabetes through deacetylation of NFkB-p65 and histone 3,” The Journal of Nutritional Biochemistry, vol. 26, no. 11, pp. 1298–1307, 2015.

[29] X. Peng, J. Li, S. Tan et al., “COX-1/PGE2/EP4 alleviates mucosal injury by upregulating β-arr1-mediated Akt signaling in colitis,” Scientific Reports, vol. 7, no. 1, p. 1055, 2017.

[30] W. L. Lau, S.-M. Liu, S. Pahlevan et al., “Role of Nrf2 dysfunction in uremia-associated intestinal inflammation and epithelial barrier disruption,” Digestive Diseases and Sciences, vol. 60, no. 5, pp. 1215–1222, 2015.

[31] M. K. Jeengar, D. Thummuri, M. Magnusson, V. G. M. Naidu, and S. Uppugunduri, “Uridine ameliorates dextran sulfate sodium (DSS)-Induced colitis in mice,” Scientific Reports, vol. 7, no. 1, p. 3924, 2017.

[32] G. Rogler, “Chronic ulcerative colitis and colorectal cancer,” Cancer Letters, vol. 345, no. 2, pp. 235–241, 2014.

[33] H. A. Kazi and Z. Qian, “Crocetin reduces TNBS-induced experimental colitis in mice by downregulation of NFkB,” Saudi Journal of Gastroenterology, vol. 15, no. 3, pp. 181–187, 2009.

[34] F. Dong, H. Tian, S. Yan et al., “Dihydroartemisinin inhibits endothelial cell proliferation through the suppression of the ERK signaling pathway,” International Journal of Molecular Medicine, vol. 35, no. 5, pp. 1381–1387, 2015.

[35] Sarina, Y. Yagi, O. Nakano et al., “Induction of neurite outgrowth in PC12 cells by artemisinin through activation of ERK and p38 MAPK signaling pathways,” Brain Research, vol. 1490, pp. 61–71, 2013.

[36] B. Zhang, P. Liu, Y. Zhou et al., “Dihydroartemisinin attenuates renal fibrosis through regulation of fibroblast proliferation and differentiation,” Life Sciences, vol. 223, pp. 29–37, 2019.

[37] D. Yang, W. Yuan, C. Lv et al., “Dihydroartemisinin suppresses inflammation and fibrosis in bleomycin-induced pulmonary fibrosis in rats,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 2, pp. 1270–1281, 2015.

[38] S. Saito, Y. Zhuang, B. Shan et al., “Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway,” PLoS One, vol. 12, no. 10, Article ID e0186615, 2017.